Literature DB >> 26549244

Resveratrol inhibits mucus overproduction and MUC5AC expression in a murine model of asthma.

Zhen-Hua Ni1, Ji-Hong Tang2, Guo Chen2, Yi-Min Lai2, Qing-Ge Chen2, Zao Li2, Wei Yang2, Xu-Min Luo2, Xiong-Biao Wang2.   

Abstract

Previous in vitro studies have demonstrated that resveratrol is able to significantly inhibit the upregulation of mucin 5AC (MUC5AC), a major component of mucus; thus indicating that resveratrol may have potential in regulating mucus overproduction. However, there have been few studies regarding the resveratrol‑mediated prevention of MUC5AC overproduction in vivo, and the mechanisms by which resveratrol regulates MUC5AC expression have yet to be elucidated. In the present study, an ovalbumin (OVA)‑challenged murine model of asthma was used to assess the effects of resveratrol treatment on mucus production in vivo. The results demonstrated that resveratrol significantly inhibited OVA‑induced airway inflammation and mucus production. In addition, the mRNA and protein expression levels of MUC5AC were increased in the OVA‑challenged mice, whereas treatment with resveratrol significantly inhibited this effect. The expression levels of murine calcium‑activated chloride channel (mCLCA)3, an important key mediator of MUC5AC production, were also reduced following resveratrol treatment. Furthermore, in vitro studies demonstrated that resveratrol significantly inhibited human (h)CLCA1 and MUC5AC expression in a dose‑dependent manner. These results indicated that resveratrol was effective in preventing mucus overproduction and MUC5AC expression in vivo, and its underlying mechanism may be associated with regulation of the mCLCA3/hCLCA1 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26549244     DOI: 10.3892/mmr.2015.4520

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  [Brahma-related gene 1 promotes airway mucus hypersecretion via STAT6 in asthmatic mice].

Authors:  Shuang Cai; Wenjing Zou; Ting Wang; Yaping Wang; Fengxia Ding; Daiyin Tian; Chao Niu; Lin Zou; Zhou Fu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

Review 2.  Resveratrol as a potential therapeutic drug for respiratory system diseases.

Authors:  Xiao-Dan Zhu; Xiao-Ping Lei; Wen-Bin Dong
Journal:  Drug Des Devel Ther       Date:  2017-12-15       Impact factor: 4.162

Review 3.  Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights.

Authors:  Diego de Sá Coutinho; Maria Talita Pacheco; Rudimar Luiz Frozza; Andressa Bernardi
Journal:  Int J Mol Sci       Date:  2018-06-20       Impact factor: 5.923

4.  Investigation of the Active Ingredients and Mechanism of Polygonum cuspidatum in Asthma Based on Network Pharmacology and Experimental Verification.

Authors:  Junjie Bi; Yuhua Lin; Yipeng Sun; Mengzhe Zhang; Qingge Chen; Xiayi Miu; Lingling Tang; Jinjin Liu; Linyun Zhu; Zhenhua Ni; Xiongbiao Wang
Journal:  Drug Des Devel Ther       Date:  2021-03-09       Impact factor: 4.162

Review 5.  Resveratrol in the treatment of asthma based on an animal model.

Authors:  Kamil Leis; Przemysław Gałązka; Jakub Kazik; Tomasz Jamrożek; Weronika Bereźnicka; Rafał Czajkowski
Journal:  Postepy Dermatol Alergol       Date:  2022-07-15       Impact factor: 1.664

6.  Ameliorative effects of eosinophil deficiency on immune response, endoplasmic reticulum stress, apoptosis, and autophagy in fungus-induced allergic lung inflammation.

Authors:  Sijiao Wang; Zhilong Jiang; Liyang Li; Jun Zhang; Cuiping Zhang; Changzhou Shao
Journal:  Respir Res       Date:  2021-06-07

7.  Curcumin Inhibits Growth of Human NCI-H292 Lung Squamous Cell Carcinoma Cells by Increasing FOXA2 Expression.

Authors:  Lingling Tang; Jinjin Liu; Linyun Zhu; Qingge Chen; Ziyu Meng; Li Sun; Junsheng Hu; Zhenhua Ni; Xiongbiao Wang
Journal:  Front Pharmacol       Date:  2018-02-02       Impact factor: 5.810

8.  Different effects of acetyl-CoA carboxylase inhibitor TOFA on airway inflammation and airway resistance in a mice model of asthma.

Authors:  Fang-Fang Zhu; Yi-Min Wang; Guang-Zhen He; Yi-Fei Chen; Ya-Dong Gao
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.